Our Prostate Cancer community was happy when Bayer and Algeta announced an Early/Expanded Access Program for Alpharedin. However we notice that, as of today, there is only one clinical trial site that is currently open and taking any new patients. However, this site is limited to only 2 men per month and their waiting list [...]
There has been a lot of news in the area of early access for great drugs to treat advanced prostate cancer prior to the FDA’s approval. I have informed you about the Early Access Program for MDV-3100 in men with castrate resistant prostate cancer previously treated with a Docetaxel based chemotherapy agent. The latest news [...]
Algeta announced that updated data from the phase III trial, ALSYMPCA, for its investigational drug Alpharadin (radium-223 dichloride). The data confirmed the overall survival of men with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases using Alpharadin, compared to the interim analysis from June 2011. • Overall survival in Alpharadin arm increased by 44% • [...]
Radium-223 Chloride (Alpharadin) is now available for the treatment of men with advanced prostate cancer who have symptomatic bone metastases (painful) and who are also castration-resistant (hormone-refractory). This is an expanded access program that will allow the use of Alpharadin prior to the formal FDA approval of the treatment. From the Clinical Trials Web Page [...]
I am interrupting the reviews of the AACR meeting to inform you of a very important piece of news. Men with advanced prostate cancer which is castrate resistant and who have 2 blaistic bone metastases may now have access to Alpharadin even though the FDA has not yet approved it in the United States! It [...]